Combining chemotherapy and targeted therapies in metastatic colorectal cancer

World Journal of Gastroenterology

Volumn 13, Issue 44, 2007, Pages 5867-5876

  Rodriguez, Javier ^a   Zarate, R ^a   Bandres, E ^a   Viudez, A ^a   Chopitea, A ^a   Garcia Foncillas J ^a   Gil Bazo, I ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Chemotherapy; Clinical trials; Colorectal cancer; Combinations; Targeted therapy

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 7 HYDROXYSTAUROSPORINE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CELECOXIB; CETUXIMAB; ERLOTINIB; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; OBLIMERSEN; OXALIPLATIN; PANITUMUMAB; PELITINIB; PLACEBO; RAPAMYCIN; ROFECOXIB; SEMAXANIB; TEMSIROLIMUS; TOPOTECAN; UNINDEXED DRUG; VANDETANIB; VATALANIB; VORINOSTAT;

ACNE; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; HYPERBILIRUBINEMIA; HYPOMAGNESEMIA; KIDNEY FAILURE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SALVAGE THERAPY; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; SURVIVAL TIME; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 36348963081     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i44.5867     Document Type: Review

References (87)

1. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553-4560
2. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676
3. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001; 92: 1331-1346
4. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4: S9-S15
5. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res 2000; 6: 747-753
6. Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, LoBuglio A. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor rector (EGFR). Proc Am Soc Clin Oncol 2001; 20: 7 (Abstract)
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345
8. Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aranda Aguilar A, Aapro M, Van Den Berg N, Eggleton S, Siena S. MABEL. A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. Proc Am Soc Clin Oncol 2006; 158s: 3549 (Abstract)
9. Abubakr Y, Eng C, Wong L, Pautret V, Scheithauer W, Maurel J, Kroening H, lutz M, Zubel A, Sobrero A. Cetuximab plus irinotecan for metastatic colorectal cancer: Safety analysis of 800 patients in a randomized phase III trial. Proc Am Soc Clin Oncol 2006; 160s: 3556 (Abstract)
10. Vincenzi B, Santini D, Tonini G. Lack of response of cetuximab plus oxaliplatin in advanced colorectal cancer patients resistant to both oxaliplatin and cetuximab plus irinotecan. Ann Oncol 2006; 17: 527-528
11. Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Trodella L, Tonini G. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 2006; 94: 792-797
12. Smith DM, Legoux J, Brunet R, Adhoute X, Blanc J, Fonck M, Vendrely V, Becouarn Y. Cetuximab in combination with FOLFIRI in second and third line treatment of metastaic colorectal cancer: Safety and efficacy analysis. Proc Am Soc Clin Oncol 2006; 160s: 3558 (Abstract)
13. Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S, benson A, Wade J, Schilsky R, Mayer R. Phase III study of FOLFIRI or FOLFOX with or without cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum: CALGB 80203 preliminary results. Proc Am Soc Clin Oncol 2006; 148s: 3509 (Abstract)
14. Heinemann V, Fischer Von Weikersthal L, Moosmann N, Vehling-Kaiser U, Stauch M, Oruzio D, Schulze M, Walther J, Weiss J, Dietzfelbinger H. Cetuximab + capecitabine + irinotecan versus cetuximab + capecitabine + oxaliplatin as first line therapy for patients with metastatic colorectal cancer: Preliminary results of a randomized phase II trial of the AIO CRC Study Group. Proc Am Soc Clin Oncol 2006; 158s: 3550 (Abstract)
15. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P, Kohne CH. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17: 450-456
16. Dakhil S, Cosgriff T, Headley D, Boccia RV, Badarinath S. Cetuximab plus FOLFOX-6 as first line therapy for metastatic colorectal cancer. (An International Oncology Network study, I-03-002.). Proc Am Soc Clin Oncol 2006; 160s: 3557 (Abstract)
17. Colucci G, Giuliani F, Mattioh R, Garufi C, Mallamaci R, Pezella G, Lopz M, Maiello E. FOLFOX-4 plus cetuximab in untreated patients with advanced colorectal cancer. A phase II study of the Gruppo Oncologico dell'Italia Meridionale (prot GOIM 2402. Proc Am Soc Clin Oncol 2006; 160s: 3559 (Abstract)
18. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, Zampino M, Donea S, Ludwig H, Zubel A, Koralewski P. Cetuximab plus FOLFOX versus FOLFOX4 in the first line treatment of metastatic colorectal cancer: OPUS, a randomized phase II study. Proc Am Soc Clin Oncol 2007; 172s: 4035 (Abstract)
19. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J, Kohne C. Randomized phase III study of FOLRIRI with or without Cetuximab in the first line treatment of patients with metastatic colorectal cancer: The CRYSTAL trial. Proc Am Soc Clin Oncol 2007; 164s: 4000 (Abstract)
20. Hecht J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, Yang L, McDonald M, Berlin J. Panitumumab in combination wiyh 5-fluorouracil, leucovorin, and irinotecan or FOLFIRI for first line treatment of metastatic colorectal cancer. Proc Am Soc GI Symp 2006: 237 (Abstract)
21. Teipar S, Peeters M, Humblet Y, Gelderblom H, Vermorken J, Viret F, Glimelius F, Ciardiello F, Kisker O, Van Cutsem E. Phase I/II study of cetuximab dose escalation in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study). Pharmacokinetic, Pharmacodynamic and efficacy data. Proc Am Soc Clin Oncol 2007; 172s: 4037 (Abstract)
22. Gravalos C, Sastre J, Aranda E, Massuti B, Vega-Villegas ME, Gomez A, Varella-Garcia M, Jimeno A, Diaz-Rubio E, Hidalgo M. Analysis of potential predictive factors of clinical benefit in patients with matastatic colorectal cancer treated with single agent cetuximab as first line treatment. Proc Am Soc Clin Oncol 2007; 193s: 4120 (Abstract)
23. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta. M, Siena S, Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286
24. Garufi C, Mottolese M, Cianciulli A, Zeuli M, Buglioni S, Torsello A, Vanni B, Campanellaa C, Merola R, Terzoli E. Epidermal growth factor gene amplification is not frequent and cannot account for antitumor activity of cetuximab plus chemotherapy in advanced colorectal cancer patients. Proc Am Soc Clin Oncol 2006; 161s: 3561 (Abstract)
25. Di Fiore F, Le Pessot F, Lamy A, Charbonnier F, Sabourin J, Paillot B, Frebourg T, Michel P. K-ras mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer. Proc Am Soc Clin Oncol 2007; 565s: 10502 (Abstract)
26. Zhang W, Yun J, Press CIA, Gordon M, Yang DY, Mallik N, Sherrod A, Iqbal S, Lenz HJ. Association of cychn D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225). Proc Am Soc Clin Oncol 2004: 3518 (Abstract)
27. Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA, Shackney SE. HER2 expression as a potential marker for response to therapy targeted to the EGFR. Br J Cancer 2006; 94: 1144-1153
28. Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S, Lenz HJ. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005; 23: 3536-3544
29. Finocchiaro G, Capuzzo F, Janne PA, Bencardino K, Carnaghi C, Franklin WA, Roncalli M, Crino L, Santoro A, Varella-Garcia M. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. Proc Am Soc Clin Oncol 2007; 168s: 4021 (Abstract)
30. Nagashima F, Zhang W, Gordon M, Chang HM, Lurje G, Borucka E, Yang D, Rowinsky E, Lenz HJ. EGF, Cox-2 and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab. Proc Am Soc Clin Oncol 2007; 195s: 4129 (Abstract)
31. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001; 7: 1459-1465
32. Rothenberg ML, Lafleur B, Washington MK, Levy DE, Morgan-Meadows DE, Ramanathan RK, Berlin JD, Benson AIB, Coffey RJ. Changes in epidermal growth factor receptor signalling in serum and tumour biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): An Eastern Cooperative Oncology Group Meeting. Proc Am Soc Clin Oncol 2004; 21: 3000 (Abstract)
33. Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH Jr, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 2005; 23: 165-170
34. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063
35. Magne N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renee N, Marchetti S, Etienne MC, Milano G. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003; 9: 4735-4742
36. Hammongd LA, Figueroa J, Schawrtzaberg L: Feasibility and pharmacokinetic (PK) trial of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with 5-Fluororaucil (3-FU) and lecovorin (LV) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2001: 544 (Abstract)
37. Jimeno A, Sevilla I, Gravalos C. Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line, therapy. Proc Am Soc Clin Oncol 2005; 23: 3176a
38. Chau I, Massey A, Higgins L, Botwood N, Cunningham D. Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2004; 23: 263 (Abstract)
39. Veronese ML, Sun W, Giantonio B, Berlin J, Shults J, Davis L, Haller DG, O'Dwyer PJ. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br J Cancer 2005; 92: 1846-1849
40. Hochhaus A, Hofheinz R, Heike M. Phase I study of gefitinib in combination with FOLFIRI as 2nd-/3rd-line treatment in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005; 23: 3674 (Abstract)
41. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 5613-5619
42. Zeuli M, Gelibter A, Nardoni C. A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2004; 23: 306 (Abstract)
43. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739-748
44. Townsley CA, Major P, Siu LL, Dancey J, Chen E, Pond GR, Nicklee T, Ho J, Hedley D, Tsao M, Moore MJ, Oza AM, Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br J Cancer 2006; 94: 1136-1143
45. Ouchi KF, Yanagisawa M, Sekiguchi F, Tanaka Y. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 2006; 57: 693-702
46. Nakhoul, Grossbard M, Blum R, Malamud S, Rodriguez T, Takhir M, Kozuch P. Phase II study of erlotinib in combination with capecitabine in previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol GI Symp 2006: 239 (Abstract)
47. Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol 2006; 24: 1892-1897
48. Nunes M, Shi C, Greenberger LM. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther 2004; 3: 21-27
49. Casado E, Folprecht L, Paz-Ares L. A Phase I/IIA pharmacokinetic and serial skin and tumor pharmacodynamic study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil leucovorin and irinotecan (FOLFIRI regimen) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: 256 (Abstract)
50. Tejpar S, Van Cutsem E, Gamelin E. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2004; 23: 265 (Abstract)
51. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
52. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
53. Kabbinavar F, Sulo A, Irl C, Nurwitz N. Bevacizumab improves outcomes of patients with metastasic colorectal cancer treated with IFL with or without bevacizumab independent of baseline risk. J Clin Oncol 2006; 24: 3539 (Abstract)
54. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
55. Saltz L, Clarke S, diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, lichinister M, Yang T, Cassidy J. Bevacizumab in combination with XELOX or FOLFOX: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first line metastatic colorectal cancer. Proc Am Soc Clin Oncol 2007; 170s: 4028 (Abstract)
56. Kretzschmar A, Van Cutsem E, Michael M, rivera F, Berry S, DiBartolomeo M, Mazier M, Lutiger B, Cunningham D. Preliminary efficacy of bevacizumab witj first line FOLFOX, XELOX, FOLFIRI and monotherapy for m CRC: First BEATrial. Proc Am Soc Clin Oncol 2007; 181s: 4072 (Abstract)
57. Reinacher-Schick A, Freier W, Dietrich G, Arnold D, Kanzler S, Geissier S, Graeven U, Hegewisch-Becker S, Schmoll H. Comparable safety and response rate with bevacizumab in combination with capecitabine/ oxaliplatin versus capecitabine/irinotecan in advanced CRC: A randomized phase II study of the AIO GI tumor study group. Proc Am Soc Clin Oncol 2007; 172s: 4034 (Abstract)
58. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24: 3354-3360
59. Grothey A, Sugrue M, Hedrick E, Purdie D, Yi J, Dong W, Kozloff M. Association between exposure to bevacizumab beyond first progression and overall survival in patients with metastatic colorectal cancer: Results forn a large observational study (BRiTE). Proc Am Soc Clin Oncol 2007; 172s: 4036 (Abstract)
60. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106
61. Rosen P, Amado R, Hecht J. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000; 18: 5a
62. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002; 5: 237-256
63. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189
64. Steward W, Thomas A, Morgan B. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis; inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 23: 3556 (Abstract)
65. Schleucher N, Trarbach T, Junker U, Tewes M, Masson E, Lebwohl D, Seeber S, Laurent D, Vanhoefer U. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2005; 23: 3605 (Abstract)
66. Major P, Trarbach T, Lenz H, Kerr D, Pendergrass K, Douillard J, Chen B, Laurent D, Jacqes C, Van Cutsem E. A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients with metastatic colorectal cncer receiving FOLFOX and PTK/ZK to determine clinical benefit on progression free survival in high LDH patients. J Clin Oncol 2006; 18s: 3529 (Abstract)
67. Lorusso PM, heath E, Valdivieso M, Pilat M, Wozniak A, Gadgeel S, Shields A, Puchalski R. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. J Clin Oncol 2006; 24: 3034 (Abstract)
68. Michael M, Tebbutt N, Gibbs P, Smith R, Godwood A, Oliver S. Vandetanib with FOLFOX6 in advanced colorectal adenocarcinoma: An open-label multicenter phase I study. Proc Am Soc Clin Oncol 2007; 187s: 4095 (Abstract).
69. Saunders M, Van Cutsem E, Wilson R, Peeters M, Smith R, Godwood A, Oliver S. Vandetanib with FOLFIRI in advanced colorectal adenocarcinoma: An open-label multicenter phase I study. Proc Am Soc Clin Oncol 2007: 184s: 4085 (Abstract)
70. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006; 24: 217-227
71. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981-989
72. Shaye OS, Chang HM, Yang DY, Shriki J, Schutheis AM, Zhang W, Lurje G, Iqbal S, Lenz HJ. Polymorphisms in angiogenesis related genes predict clinical outcome in patients with metastatic colorectal cancer treated with first line 5-FU or caapecitabine in combination with oxaliplatin and bevacizumab. Proc Am Soc Clin Oncol 2007: 548s: 10576 (Abstract)
73. Tournigand C, Iledo G, Delord J, Andre T, Maindrault-Goebel F, Louvet C, Scheithauer W, de Gramont A. Modified Folfox/bevacizumab or modified Xelox/bevacizumab with or without erlotinib in first line metastatic colorectal cancer. Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR). Proc Am Soc Clin Oncol 2007: 187s: 4097 (Abstract)
74. Ocean AJ, Brien K, Lee J, Matthews N, Holloway S, Christos P, Kung TS, Kaubisch A, Chen H, Wadler S. Phase II trial of FOLFOX, bevacizumab and cetuximab in patients with colorectal cancer. Proc Am Soc Clin Oncol 2007: 182s: 4075 (Abstract)
75. Schwartzberg LS, Hurwitz H, Stephenson J, Kotasek D, Goldstein D, Tebbutt N, Greivy J, Sun Y, Yang L, Burris H. Safety and pharmacokinetics of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients with metastatic colorectal. cancer. Proc Am Soc Clin Oncol 2007: 183s: 4081 (Abstract)
76. Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005; 23: 1875-1884
77. Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh IT, Izbicka E, Berg K, Tolcher AW. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 2006; 17: 313-321
78. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle D, Wright J, Siu L, Moore M, Oza A. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezornib in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11: 5526-5533
79. Lacombe DA, Caponigro F, Anthoney A, bauer J, Govaerts A, Milano A, Marreaud S, Twelves C. A phase I study of bortezomib in combination with FOLFOX4 in patients with advanced colorectal cancer: EORTC 16029. Proc Am Soc Clin Oncol 2007: 186s: 4090 (Abstract)
80. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003; 4: 605-615
81. Morabito A, Gattuso D, Sarmiento R. Rofecoxib associated with an antiangiogenic schedule of weekly irinotecan and infusional 5-fluorouracil as second line treatment of patients with metastatic colorectal cancer: Results of a dose-finding study. Proc Am Soc Clin Oncol 2003; 22: 326 (Abstract)
82. Fuchs C, Marshall J, Mitchell E, Wieirzbicki R, Ganju V, Jeffery M, Schultz J, Richards DA, Soufi-Mahjoubi R, barrueco J. Updated results of BICC-C study comparing first line irinotecan/fluoropyrimidine combinations with or without celecoxib in CRC: Updated efficacy data. Proc Am Soc Clin Oncol 2007; 170s: 4027 (Abstract)
83. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998; 12: 599-606
84. Fakih MG, Pendyala L, Toth K, Creaven P, Soehnlein N, Litwin A, Trump D. A phase I Study of vorinostat in combination with FOLFOX in patients with advanced colorectal cancer. J Clin Oncol 2006; 24: 3592 (Abstract)
85. Klupp J, Langrehr JM, Junge G, Neuhaus P. Inhibitors of mammalian target of rapamycin. Drugs Fut 2001, 26: 1179-1188
86. Skotnicki JS, Leone CL, Smith AL, Palmer Y, Yu K, Discafani CM, Gibbons JJ, Frost P, Abou-Gharbia MA. Design, synthesis and biological evaluation of C42 hydrox-yesters of rapamycin: The identification of CCI-779. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther 2001: 477 (Abstract)
87. Punt CJA, Bruntsch U, Hanauske AR, Weigang-Kohler, K., Peters M, Thielert C, Frisch J. A phase I study of escalating doses of CCI-779 in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Eur J Cancer 2001; 37: 53 (Abstract)